

---

## DIGEST

The digest printed below was prepared by House Legislative Services. It constitutes no part of the legislative instrument. The keyword, one-liner, abstract, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

---

HB 316 Original

2021 Regular Session

Davis

**Abstract:** Provides that mucopolysaccharidosis type I (MPS I) and glycogen storage disorder type II (Pompe) diseases shall be added to the list of genetic conditions tested by physicians attending newborn children.

Present law provides that a physician attending to the care of a newborn child shall cause the child to be subjected to a list of genetic conditions provided for in present law that have been approved by the La. Dept. of Health. Further provides that the genetic conditions shall be tested upon approval by the newborn child's parents.

Proposed law retains present law and adds that of the genetic conditions provided by present law, MPS I and Pompe diseases shall be genetic conditions approved by the La. Dept. of Health and shall be tested by physicians attending newborn children, upon the approval by the child's parents.

Proposed law supersedes amendments to present law, R.S. 40:1081.2(A)(1), made by §1 of Act No. 507 of the 2016 Regular Session.

Effective Jan. 1, 2022.

(Amends R.S. 40:1081.2(A)(1))